Paul Baas

Paul Baas

Netherlands Cancer Institute - Amsterdam / Netherlands
Others
AD Scientific Index ID: 4963195
Nederlands Kanker Instituut
person_outline Paul Baas's MOST POPULAR ARTICLES
1-) Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer J Brahmer, KL Reckamp, P Baas, L Crinò, WEE Eberhardt, ... New England Journal of Medicine 373 (2), 123-135, 2015 78662015
2-) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial RS Herbst, P Baas, DW Kim, E Felip, JL Pérez-Gracia, JY Han, J Molina, ... The Lancet 387 (10027), 1540-1550, 2016 57302016
3-) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ... Journal of Thoracic Oncology 11 (1), 39-51, 2016 30152016
4-) Photodynamic therapy in oncologyM Triesscheijn, P Baas, JHM Schellens, FA StewartThe oncologist 11 (9), 1034-1044, 20069682006
5-) First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trialP Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ...The Lancet 397 (10272), 375-386, 20219272021